Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la vessie

Rouprêt, Morgan; Neuzillet, Y.; Masson-Lecomte, A.; Colin, Philippe; Compérat, Éva; Dubosq, Francis; Houédé, Nadine; Larré, S.; Pignot, G.; Puech, P; Roumiguié, M.; Xylinas, E.; Méjean, Arnaud

doi:10.1016/s1166-7087(16)30704-7

Cited by 59 publications

(16 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This comparative retrospective analysis of real-world data on prevailing TURB treatments of BCa showed that in Germany only 20% of GKV-insured persons with BCa receive initial BL-TURB, despite its therapeutic benefits compared to WL-TURB and its recommendation in guidelines [3,25]. Availability of equipment and acquisition costs as well as additional costs of HAL may restrict the use of BL-TURB in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Todenhöfer

Maas

Ketz³

et al. 2021

World J Urol

View full text Add to dashboard Cite

Purpose Photodynamic diagnosis using hexaminolevulinate (HAL)—guided BL-TURB may reduce the recurrence risk in non-muscle invasive BCa compared to standard WL-TURB due to more sensitive tumor detection. The impact of the initial use of WL- vs. BL-TURB on follow-up costs was evaluated in this real-world data analysis. Methods Anonymous claims data of German statutory health insurances (GKV) from 2011 to 2016 were analyzed in a primary and adjusted study population. Selection criteria included five quarters before enrolment, one index quarter (InQ) of initial TURB and BCa diagnosis, either within two years for the primary analysis or within four years for the adjusted analysis, and a follow-up period (FU) of either eleven or three quarters, respectively. Results In the primary analysis (n = 2331), cystectomy was identified as an important cost driver masking potential differences between cohorts. Therefore, patients undergoing cystectomy (InQ + FU) were excluded from the adjusted study population of n = 4541 patients (WL: 79%; BL: 21%). Mean total costs of BL-TURB were initially comparable to WL-TURB (WL: EUR 4534 vs. BL: EUR 4543) and tended to be lower compared to WL-TURB in the first two quarters of FU. After one year (3rd FU quarter), costs equalized. Considering total FU, mean costs of BL-TURB were significantly lower compared to WL-TURB (WL: EUR 7073 vs BL: EUR 6431; p = 0.045). Conclusion This retrospective analysis of healthcare claims data highlights the comparability of costs between BL-TURB and WL-TURB.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Todenhöfer

Maas

Ketz³

et al. 2021

World J Urol

View full text Add to dashboard Cite

show abstract

“…At least 87% of all physicians reported that they follow guidelines for the treatment of NMIBC ( Table 1). The EAU NMIBC guidelines are the most followed guidelines, except in France and the Netherlands where the national guidelines are most followed [12,13]. In France, this preference seems to stem from the national guidelines being in the native language ( Table 1).…”

Section: Guidelinesmentioning

confidence: 99%

Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey

Hendricksen

Aziz

Bes

et al. 2019

European Urology Focus

View full text Add to dashboard Cite

show abstract

“…The estimated frequency was based upon the previous Association Française d'Urologie guidelines indicating the use of hexaminolevulinate when a high-risk lesion was suspected [2] , but the European registration of the product provides a broader indication ("in patients with known or high suspicion of bladder cancer"). The more frequent use of hexaminolevulinate in the HOPE study may reflect the recent update of the French guidelines, which recommend the use of hexaminolevulinate for diagnosis at every TURB [22] . This situation may explain why the frequency of use was difficult to predict.…”

Section: Discussionmentioning

confidence: 99%

Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to Expect

Jacqmin

Jichlinski²,

Molinier³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Objective: The Hexvix® Observational Patients Evaluation (HOPE) study was designed to determine the extent of distribution of the use of hexaminolevulinate in the diagnosis of non-muscle invasive bladder cancer (NMIBC) and assess patient and treatment characteristics associated with different endoscopic modalities and to address the French authorities' request for information on routine practices for NMIBC diagnosis and surveillance. Patients and Methods: A prospective, observational study in 30 centres in France with fluorescence endoscopy equipment available. All candidates for endoscopy with transurethral resection who gave their consent were eligible. The primary endpoint was the proportion of patients with an NMIBC diagnosis performed with hexaminolevulinate. Results: 506 patients were included: 252 (49.8%) diagnosed with hexaminolevulinate and 254 (50.2%) with white-light endoscopy alone. There were more patients with tumour recurrence, multiple lesions, lesions with a diameter <3 cm, stage Ta disease, and grade 1 lesions in the hexaminolevulinate group. The first quartile median recurrence-free survival time was 310 days in the hexaminolevulinate group and 144 days in the standard-endoscopy group (p = 0.0015). Conclusion: Hexaminolevulinate was in frequent use in France with specific patient and disease characteristics associated with its use. HOPE illustrates the type of data that can be gained in post-authorisation studies to address requests from European health authorities.

show abstract

Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la vessie

Cited by 59 publications

References 91 publications

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey

Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to Expect

Contact Info

Product

Resources

About